Delivery Order SPE2DB22D3501-SPE2DB24FTT12
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award, valued at $79,357.76, is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for...
- This federal contract award, valued at $12,574.87, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a completion date of December 15, 2023. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December...
- This federal contract award, valued at $10,925.98, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of the pharmaceutical product XIFAXAN 550 mg Tablet 60s. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. The IDC serves as a primary...
- The U.S. government agency, the Defense Logistics Agency (DLA), awarded a Delivery Order contract valued at $2,944.99 to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of the pharmaceutical product XIFAXAN 550 MG TABLET 60S, with a completion date of December 11, 2023. This contract is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, at a ceiling value of $48,281.46. The contract has an ultimate completion date of November 20, 2023 and was awarded on November 17, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $12,978.74, is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has a ceiling value of $12,978.74 and an ultimate completion date of November 20, 2023. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc....
- This federal contract award is a delivery order (SPE2DB20D1110|SPE2DB24FK18S) with a ceiling value of $2,082.38, awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the supply of XIFAXAN 550 MG TABLET 60S to the Defense Logistics Agency (DLA), a defense agency. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC...
- This federal contract award, issued by the Defense Logistics Agency (DLA) Troop Support Medical, is a Delivery Order valued at $42,891.12 for the pharmaceutical product XIFAXAN 550 MG TABLET 60S. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026....
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $3,399.60 for the supply of XIFAXAN 550 MG tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation, indicating open competition. The award is associated with a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical division. This IDC serves as the primary...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of XIFAXAN 550 MG TABLET 60S. The award, valued at $1,398.21, is a firm fixed-price contract with an ultimate completion date of January 18, 2022. This order is placed under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. The IDC...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB24FTT12Delivery Order
This federal contract award, valued at $16,368.85, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, to support military healthcare programs. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Cencora, Inc. to provide a wide range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and other federal agencies. The contract does not have a set-aside designation, indicating full and open competition. No subcontractors were identified in the provided information.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.4k | 12/4/23 |